Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

91.35 +0.86 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
52 53 Next >
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
Via The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Exposures Supply Chain
A Look Into Gilead Sciences' Debt
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Analyst Expectations for Gilead Sciences's Future
Via Benzinga
3 Stocks to Buy Right Now That Are Cash Cows
If cash is king, these three stocks should wear crowns. 
Via The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
2 Healthcare Stocks That Could Help Set You Up for Life
Even seemingly boring businesses can deliver solid returns over long periods. 
Via The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
7 Cash-Rich Companies to Invest in During Economic Uncertainty
Although they’re not necessarily the most exciting enterprises, these cash-rich stocks should keep your portfolio upright. 
Via InvestorPlace
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today
Via Benzinga
Elliott Wave Technical Analysis: Gilead Inc.
Looking for a clear three wave move in wave (ii) to then place longs. 
Via Talk Markets
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Via Benzinga
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
From Gilead Sciences, Inc.
Via Business Wire
Kite Completes Acquisition of Tmunity
From Gilead Sciences, Inc.
Via Business Wire
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
From Gilead Sciences, Inc.
Via Business Wire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer... 
Via SBWire
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero... 
Via SBWire
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
From Gilead Sciences, Inc.
Via Business Wire
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares... 
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).  
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.